InfuSystem Holdings reported a solid finish to 2025 with record net revenues and significant growth in net income and Adjusted EBITDA, driven by strong performance in both Patient Services and Device Solutions segments. The company is strategically restructuring a key contract to prioritize profitability and is investing in technology upgrades to enhance efficiency, positioning for continued growth in 2026.
Full Year Net revenues reached a record $143.4 million, up 6% year-over-year.
positiveFull Year Net income increased significantly to $6.6 million, up 183% year-over-year.
positiveFull Year Adjusted EBITDA reached a record $31.5 million, up 24% year-over-year, with a margin of 21.9%.
positiveFull Year Operating Cash Flow increased 19% to a record $24.4 million.
positiveFourth Quarter Net revenues increased 7% to $36.2 million.
positiveFourth Quarter Gross margin improved to 56.4%, up 2.6% year-over-year.
positiveFourth Quarter Operating income increased 42% to $3.7 million.
positiveFourth Quarter Net income increased 118% to $2.0 million.
positiveFourth Quarter Adjusted EBITDA increased 17% to $8.8 million, with a margin of 24.3%.
positiveNet debt decreased by $6.9 million year-over-year to $16.4 million.
positiveWound Care treatment revenue grew by 160% in the fourth quarter.
positiveThe restructuring of the largest biomedical services contract will reduce annual revenue by $7.1 million (5.5%) in 2026.
attentionFourth Quarter Operating Cash Flow decreased 10% to $7.1 million compared to the prior year.
attentionPatient Services gross margin decreased by 1.1% year-over-year in the fourth quarter.
attentionSelling and marketing expenses as a percentage of net revenues increased by 0.4% year-over-year in the fourth quarter.
attentionGeneral and administrative expenses increased by $0.9 million in the fourth quarter, including $0.2 million for IT upgrades.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Patient Services | N/A | — | — | — |
Device Solutions | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Closed out the 2025 reporting period by delivering solid top line growth of 7.0%, with full-year Adjusted EBITDA expanding 24% to $31.5 million and strong operating cash flow of $7.1 million.
Made significant progress on our new revenue cycle management platform, which is already lowering claims processing costs and improving billing efficiency, and on our enterprise technology upgrade.
Restructured our largest biomedical services contract, which will have an immediate favorable impact on our reported earnings and cash flows since we also expect an even larger reduction in our expenses. This decision reflects our focus on the quality and profitability of our revenue, not just revenue growth.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.